U.S. markets open in 41 minutes
  • S&P Futures

    3,605.50
    +29.50 (+0.82%)
     
  • Dow Futures

    29,877.00
    +331.00 (+1.12%)
     
  • Nasdaq Futures

    11,952.50
    +47.25 (+0.40%)
     
  • Russell 2000 Futures

    1,843.90
    +26.80 (+1.47%)
     
  • Crude Oil

    43.70
    +0.64 (+1.49%)
     
  • Gold

    1,803.30
    -34.50 (-1.88%)
     
  • Silver

    23.05
    -0.58 (-2.47%)
     
  • EUR/USD

    1.1868
    +0.0022 (+0.19%)
     
  • 10-Yr Bond

    0.8730
    +0.0160 (+1.87%)
     
  • Vix

    21.78
    -1.92 (-8.10%)
     
  • GBP/USD

    1.3326
    +0.0004 (+0.03%)
     
  • USD/JPY

    104.5700
    +0.0820 (+0.08%)
     
  • BTC-USD

    19,148.43
    +696.46 (+3.77%)
     
  • CMC Crypto 200

    378.49
    +17.06 (+4.72%)
     
  • FTSE 100

    6,412.05
    +78.21 (+1.23%)
     
  • Nikkei 225

    26,165.59
    +638.22 (+2.50%)
     

Eli Lilly drug gets FDA nod for emergency use with remdesivir to treat COVID-19

Nov 19 (Reuters) - The U.S. Food and Drug Administration on Thursday approved emergency use of Eli Lilly and Co's antibody drug baricitinib, in combination with remdesivir, to treat COVID-19 patients.

The drug was authorized for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring oxygen support. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)